Biopharmx Corp (NYSEAMERICAN:BPMX) saw a large increase in short interest during the month of December. As of December 29th, there was short interest totalling 6,319,421 shares, an increase of 2.3% from the December 15th total of 6,178,513 shares. Based on an average daily volume of 2,712,891 shares, the days-to-cover ratio is currently 2.3 days. Approximately 6.0% of the company’s stock are sold short.
Biopharmx (NYSEAMERICAN:BPMX) traded up $0.01 during trading hours on Wednesday, hitting $0.13. 5,858,800 shares of the stock were exchanged, compared to its average volume of 5,777,920. The company has a market cap of $14.93, a P/E ratio of -0.48 and a beta of 1.33. Biopharmx has a one year low of $0.10 and a one year high of $0.90.
Biopharmx (NYSEAMERICAN:BPMX) last announced its quarterly earnings results on Thursday, December 7th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05).
A number of equities analysts have recently commented on BPMX shares. Maxim Group reaffirmed a “buy” rating and set a $1.50 price objective on shares of Biopharmx in a report on Friday, December 8th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of Biopharmx in a report on Tuesday, September 19th.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.